Global Human Rabies Vaccines Market – Industry Trends and Forecast to 2030

Global Human Rabies Vaccines  Market, By Cell Line Type (Chick Embryo Cells, Vero Cell, BHK Cells, and Other), Application (Pre Exposure Prophylaxis and Post Prophylaxis), Route of Administration (Intravenous and Subcutaneous), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Human Rabies Vaccines Market Analysis and Size

Increasing global incidences of mortality because of rabies, the increasing issue of stray dogs in countries with low economic development are projected to drive the market over the predicted years. According to WHO, rabies cause fatalities approximately 10,000 people every year worldwide and almost 99% cases are because of dog bites. According to World Health Organization, rabies caused 59,000 deaths annually in 150 countries with 95% cases in rural districts in 2017.

Data Bridge Market Research analyses a growth rate in the human rabies vaccines market in the forecast period 2023-2030. The expected CAGR of the human rabies vaccines market tends to be around 4.7% in the mentioned forecast period. The market was valued at USD 963.53 million in 2022 and would grow to USD 1391.36 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Human Rabies Vaccines Market Scope and Segmentation

Market Definition

Rabies is typically characterized as a severe disease that is caused by the rabies virus. The humans are most likely to be infected through animal bites such as dogs, cats, bats, and other mammals. The central nervous system is affected by the rabies virus which causes severe impact to the brain and may ultimately cause death in serious cases. The major symptoms include anxiety, hallucination, insomnia, hydrophobia, paralysis hyper salivation, and others. Henceforth, early prevention from the rabies is vital with the help of vaccines.

Global Human Rabies Vaccines Market Dynamics

Drivers

• Rise In The Incidence Of Rabies

The incidence of rabies is leading to a growth in the vaccine production which boosts the growth of the market. For instance, in the U.S., rabies from early 1960 to 2000 was insignificant, and a sudden rise resulted in 100 cases yearly.  Although the fatalities were rare, lack of awareness towards rabies is proving to be a huge risk. From 1960 to 2018, 127 cases of rabies were stated in U.S. from dog bites and bat bites. However in Asia, rabies is a major burden, resulting for almost 35,000 deaths, fatalities caused by rabies in India are 55%.

• Increasing Technological Developments of Vaccines

There are various technological developments that are associated with the market which boost the growth of the market. For instance, in February 2018, BioNote, Inc., a South Korean veterinary diagnostic company that is operating in rabies diagnostics, announced the launch of a new immune-fluorescent device, Vcheck, that can measure diagnostic result values along with the help of fluorescent materials that helps in detecting the zoonotic disease in animals. Thus, these factors are expected to fuel the market growth in the coming years.

Opportunities

• Growing R&D Activities

Several market players are focused on research and development strategies that are expected to boost the market growth during the forecast period. For instance, in 2017, CPL Laboratories (India) which is a joint venture biotechnology company established in 2009 by Novavax Inc., USA and Cadila Pharmaceuticals Limited, stated that Nano-particle vaccine of baculvirous-derived glycoprotein which is a four dose regime vaccine is in phase-3 human trial, and is projected to be approved by 2021.

• Increasing Healthcare Expenditure

Growing healthcare expenditure by several organizations lead to the market expansion. For instance, in April 2022, the disease prevention and control bureau, Department of Health, Philippines, awarded Metro Drugs Inc., a procurement contract for 2,500,000 doses of purified chick embryo cell rabies vaccine. The total approved budget for this contract is 200,000,000 PHP.

 Restraints/Challenges

• High costs will derail the market growth

The huge expenditure associated with these agents impedes the market growth. For instance, as per World Health Organization, in 2017, the projected cost of PEP was US $1.5 million, which can make it too expensive in mid- or low-income countries and limit the growth of the market during the forecast period.

This human rabies vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the human rabies vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Human Rabies Vaccines  Market

The COVID-19 pandemic had a negative impact on the market. The pandemic impacted every aspect of veterinary healthcare, which includes vaccinations. For instance, according to the study titled, "The urgency of resuming disrupted dog rabies vaccination campaigns: a modeling and cost-effectiveness analysis," published in June 2021, Haiti’s 2020 dog vaccination campaign was canceled, and funds were shifted to support the COVID-19 response. According to 2020 data from the Centers for Disease Control and Prevention (CDC), cats, dogs, and several other species were at higher risk of contracting the virus. Thus, the initial impact of COVID-19 on the market growth was severe due to lockdowns, virus curbing measures, and overall negligence toward the animal sector, though such developments are estimated to boost the market growth during the coming years.

Recent Development

• In April 2022, Cadila Pharmaceuticals launched a three-dose recombinant nanoparticle-based G protein rabies vaccine in Ahmedabad. This regimen is to be given over one week (on day 0, day three, and day seven) after exposure to the virus. It is the first in a long list of existing rabies vaccines that require five doses.

Global Human Rabies Vaccines Market Scope

The human rabies vaccines market is segmented on the basis of cell line type, application, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cell Line Type

• Chick Embryo Cells
• Vero Cell
• BHK Cells
• Other

Application

• Pre Exposure Prophylaxis
• Post Prophylaxis

Route of Administration

• Intravenous
• Subcutaneous

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Human Rabies Vaccines  Market Regional Analysis/Insights

The human rabies vaccines market is analyzed and market size insights and trends are provided by cell line type, application, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the human rabies vaccines market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the human rabies vaccines market throughout the forecasted period due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.

North America dominates the market due to major product launches, high concentration of market players and manufacturers' presence, numerous acquisitions and partnerships among major players, and government initiatives toward rabies vaccination.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Human Rabies Vaccines  Market Share Analysis

The human rabies vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to human rabies vaccines market.

Key players operating in the human rabies vaccines market include:

• Serum Institute of India Pvt. Ltd (India)
• Novartis AG (Switzerland)
• Cadila Pharmaceuticals (India)
• Merck & Co., Inc. (U.S.)
• Sanofi (France)
• ADS Diagnostic Ltd (India)
• GSK plc (U.K.)
• Berna Biotech Pharma GmbH (Switzerland)
• AstraZeneca (U.K.)